Company intelligence / Profile preview

Clip Health

Milpitas, California, United Statesnih.gov ↗

Ownership: Private
Development stage: Commercial

Overview

Clip Health developed and commercialized a rapid antigen COVID test that received FDA Emergency Use Authorization in December 2020 and was distributed widely in the U.S., including to clinics, drive-through sites, employers, etc. The company also developed late-stage pipeline products for at-home COVID/influenza multiplex testing but did not achieve sustainable growth post-pandemic demand drop-off; it shut down in August 2023. Assets were acquired by Gold Colloid Co., but the company itself is defunct.

Therapeutic areas: Infectious Diseases
Modalities: DeviceDiagnostic test kit
Industry: Protein Biomarker Diagnostics

Drug pipeline

2 assets

Clip COVID Rapid Antigen Test

Commercial

Indications: COVID-19

1 more asset in the full pipeline.

Request access →

Partnerships

Khosla VenturesY CombinatorNIH

Beyond the preview

Go deeper on Clip Health.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Clip Health.

Explore the full profile